Paper42968166PubMed
Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.
Mazzocca A and 11 others. J Transl Med, 2026.
Cite this record
ConductScience Library. Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact. Papers, record 42968166. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42968166
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Checkpoint-checkpoint combinations in cancer: from mechanistic rationale to translational impact.
- Journal
- J Transl Med
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-11-05
Source PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Immune Checkpoint Inhibitors | Major topic |
| Translational Research, Biomedical | Major topic |
| Immune Checkpoint Proteins | Major topic |
| Humans | |
| Animals | |
| Immunotherapy |
Source PubMed
References84
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33811048 | Development of Immunotherapy Combination Strategies in Cancer. | Cancer Discov | 2021 | https://conductscience.org/library/papers/33811048 | PubMed |
| 2 | 40890162 | TIGIT in cancer: from mechanism of action to promising immunotherapeutic strategies. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/40890162 | PubMed |
| 3 | 37884747 | Alleviating hypoxia to improve cancer immunotherapy. | Oncogene | 2023 | https://conductscience.org/library/papers/37884747 | PubMed |
| 4 | 38057451 | Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. | Nat Rev Immunol | 2024 | https://conductscience.org/library/papers/38057451 | PubMed |
| 5 | 34093577 | The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. | Front Immunol | 2021 | https://conductscience.org/library/papers/34093577 | PubMed |
| 6 | 33485464 | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. | Lancet | 2021 | https://conductscience.org/library/papers/33485464 | PubMed |
| 7 | 40552922 | Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B. | Clin Cancer Res | 2025 | https://conductscience.org/library/papers/40552922 | PubMed |
| 8 | 40469190 | Role of TGFβ-activated cancer-associated fibroblasts in the resistance to checkpoint blockade immunotherapy. | Front Oncol | 2025 | https://conductscience.org/library/papers/40469190 | PubMed |
| 9 | 34460110 | Metabolic checkpoints and novel approaches for immunotherapy against cancer. | Int J Cancer | 2022 | https://conductscience.org/library/papers/34460110 | PubMed |
| 10 | 37857711 | The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/37857711 | PubMed |
| 11 | 37356739 | Reprogramming of cancer-associated fibroblasts combined with immune checkpoint inhibitors: A potential therapeutic strategy for cancers. | Biochim Biophys Acta Rev Cancer | 2023 | https://conductscience.org/library/papers/37356739 | PubMed |
| 12 | 41613119 | Enhancing anti-tumor immunity through co-blocking PD-L1 and TIGIT by facilitating tumor-directed responses and additional VEGF inhibition. | Front Immunol | 2025 | https://conductscience.org/library/papers/41613119 | PubMed |
| 13 | 33285141 | Enhancing anti-tumour efficacy with immunotherapy combinations. | Lancet | 2021 | https://conductscience.org/library/papers/33285141 | PubMed |
| 14 | 40171330 | Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications. | Immunotargets Ther | 2025 | https://conductscience.org/library/papers/40171330 | PubMed |
| 15 | 40234667 | First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors. | Br J Cancer | 2025 | https://conductscience.org/library/papers/40234667 | PubMed |
| 16 | 39426385 | Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China. | Lancet | 2024 | https://conductscience.org/library/papers/39426385 | PubMed |
| 17 | 41708938 | Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time? | Br J Cancer | 2026 | https://conductscience.org/library/papers/41708938 | PubMed |
| 18 | 26558876 | CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition. | Am J Clin Oncol | 2016 | https://conductscience.org/library/papers/26558876 | PubMed |
| 19 | 36933320 | Anti-TIGIT therapies for solid tumors: a systematic review. | ESMO Open | 2023 | https://conductscience.org/library/papers/36933320 | PubMed |
| 20 | 41109920 | Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/41109920 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42968166
GET https://conductscience.org/api/papers/v1/42968166/references?page=2